失眠藥物治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物、按治療、按配銷通路、按地區和競爭細分，2020-2030 年

2024 年全球失眠藥物治療市場價值為 38.1 億美元，預計到 2030 年將達到 53.3 億美元，年複合成長率(CAGR) 為 5.73%。由於全球睡眠障礙盛行率不斷上升，市場正在經歷顯著成長。壓力增加、生活方式改變以及人口老化加劇等因素加劇了對失眠藥物治療的需求。該市場包括廣泛的處方藥和非處方藥，包括苯二氮平類藥物、非苯二氮平催眠藥、褪黑激素受體激動劑和食慾素受體拮抗劑。製藥公司正致力於開發更安全、更有效的藥物，以解決與傳統睡眠輔助藥物的依賴和副作用相關的問題。監管部門對新療法的批准和藥物配方的創新進一步刺激了市場成長，為患者提供了更高的療效並減少了副作用。

人們越來越意識到不治療失眠症會帶來長期健康風險，導致失眠的診斷增多，對處方解決方案的需求也日益成長。緩釋和雙重作用配方的創新可確保整晚的持續睡眠，進而改善治療效果。此外，個人化醫療和基於生物標記的療法日益流行，正在重塑失眠治療的格局。消費者對天然、不易上癮的解決方案（如基於褪黑激素的助眠劑）的需求正在推動新產品的開發。舌下片和經皮貼片等藥物傳遞系統的進步正在擴大治療選擇，以滿足不同患者的需求。製藥公司和研究機構之間的策略合作正在加速非鎮靜性、標靶治療的開發，進一步支持市場擴張。

主要市場促進因素

失眠症盛行率不斷上升：

主要市場挑戰

長期使用的問題：

主要市場趨勢

製藥業的進步：

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球失眠藥物治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按藥物（非處方藥、非處方睡眠輔助劑、非處方睡眠補充劑、處方藥）
  • 依治療（非處方安眠藥、處方安眠藥）
  • 按配銷通路（藥局、電子商務、醫​​院藥局、零售藥局）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第 6 章：北美失眠藥物治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 7 章：歐洲失眠藥物治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太失眠藥物治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 韓國
  • 日本
  • 澳洲

第 9 章：南美洲失眠藥物治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲失眠藥物治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Merck & Co Inc
• Ebb Therapeutics Inc/US
• Pfizer Inc
• Sanofi SA
• Takeda Pharmaceutical Co Ltd
• Paratek Pharmaceuticals Inc
• Electromedical Products International Inc
• Meda Pharmaceuticals Inc
• Purdue Pharma LP
• Pernix Therapeutics Holdings Inc

第 15 章：策略建議

第16章 關於出版商,免責事項

The global insomnia pharmacological treatment market was valued at USD 3.81 billion in 2024 and is projected to reach USD 5.33 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.73%. The market is experiencing significant growth, driven by the rising prevalence of sleep disorders across the globe. Factors such as increasing stress, lifestyle changes, and the growing aging population are intensifying the demand for pharmacological treatments for insomnia. This market includes a broad spectrum of prescription and over-the-counter drugs, including benzodiazepines, non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists. Pharmaceutical companies are focusing on developing safer, more effective medications to address issues related to dependency and adverse effects associated with traditional sleep aids. Regulatory approvals for novel treatments and innovations in drug formulations are further stimulating market growth, providing patients with improved efficacy and reduced side effects.

Heightened awareness about the long-term health risks of untreated insomnia is leading to more diagnoses and a growing demand for prescription-based solutions. Innovations in extended-release and dual-action formulations are improving treatment outcomes by ensuring sustained sleep throughout the night. Additionally, the growing trend toward personalized medicine and biomarker-based therapies is reshaping the landscape of insomnia treatment. Consumer demand for natural, non-habit-forming solutions, such as melatonin-based sleep aids, is driving new product development. Advances in drug delivery systems, including sublingual tablets and transdermal patches, are expanding treatment options to meet diverse patient needs. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the development of non-sedative, targeted therapies, further supporting market expansion.

Key Market Drivers

Increasing Prevalence of Insomnia:

In today's fast-paced, digitally connected world, achieving quality sleep has become more challenging. Insomnia, characterized by persistent difficulties in falling asleep, staying asleep, or achieving restorative sleep, is on the rise. This increase in insomnia cases significantly contributes to the growth of the global pharmacological insomnia treatment market. Work-related stress, personal pressures, and constant exposure to screens have led to a substantial rise in sleep disturbances. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2020, approximately 14.5% of U.S. adults reported trouble falling asleep, and 17.8% had difficulty staying asleep regularly, underscoring the growing demand for treatment solutions.

Key Market Challenges

Concerns Over Long-Term Use:

One of the major challenges facing the global insomnia pharmacological treatment market is the concerns associated with the long-term use of medications. Prescription drugs used for insomnia treatment, such as benzodiazepines, non-benzodiazepine hypnotics, and certain antidepressants, can pose significant risks when used over extended periods. Prolonged use can lead to tolerance, dependency, withdrawal symptoms, and cognitive impairments. Over time, patients may require higher doses to achieve the same therapeutic effects, potentially leading to misuse or addiction. Furthermore, the risk of rebound insomnia when discontinuing these medications can worsen sleep disturbances. Long-term use of sedative-hypnotic medications has also been linked to adverse health effects, including cognitive decline and an increased risk of falls, particularly among elderly patients. Regulatory agencies like the U.S. FDA and the European Medicines Agency (EMA) have raised concerns about these risks, leading to stricter guidelines and closer scrutiny of chronic insomnia management.

As awareness of these issues grows, healthcare providers are exploring alternative treatments, such as cognitive behavioral therapy for insomnia (CBT-I) and lifestyle interventions, before resorting to long-term pharmacological solutions. Pharmaceutical companies face the challenge of developing new insomnia treatments that minimize dependency risks and cognitive side effects, while maintaining their effectiveness. These concerns are influencing prescription patterns, regulatory policies, and patient preferences, thereby shaping the future trajectory of the insomnia pharmacological treatment market.

Key Market Trends

Advancements in Pharmaceuticals:

The field of sleep disorders, particularly insomnia, has long been elusive, but recent advancements in pharmaceuticals are providing new insights into effective treatment options. These innovations are transforming insomnia management, offering hope and relief to individuals who have long struggled with sleep disturbances. Modern research has led to the development of new insomnia medications that are not only more effective but also safer, with fewer adverse side effects, making them more attractive to both patients and healthcare providers.

In-depth understanding of sleep regulation mechanisms has enabled the creation of targeted therapies that address specific aspects of insomnia, such as difficulties falling or staying asleep, providing more personalized and effective treatment options. Newer drugs are reducing the risks of dependency that plagued earlier sleep medications like benzodiazepines. Furthermore, some newer insomnia treatments offer longer-lasting effects, supporting sustained and restorative sleep throughout the night, improving the overall sleep experience.

Another key area of focus is minimizing next-day impairments, such as drowsiness and cognitive deficits, allowing individuals to maintain their daily activities. Advanced insomnia medications are also addressing comorbidities such as anxiety, depression, or chronic pain, offering a holistic approach to treatment.

Key Market Players:

• Merck & Co Inc.
• Ebb Therapeutics Inc. (USA)
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Paratek Pharmaceuticals Inc.
• Electromedical Products International Inc.
• Meda Pharmaceuticals Inc.
• Purdue Pharma LP
• Pernix Therapeutics Holdings Inc.

Report Scope: This report segments the global insomnia pharmacological treatment market into various categories, including industry trends and detailed analysis of the following areas:

By Drug:

• Over-the-Counter (OTC) Drugs
• OTC Sleep Aids
• OTC Sleep Supplements
• Prescription Drugs

By Treatment:

• Over-the-Counter Sleep Aids
• Prescription Sleep Aids

By Distribution Channel:

• Drug Stores
• E-Commerce
• Hospital Pharmacies
• Retail Pharmacies

By Region:

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Italy, Spain)
• Asia-Pacific (China, Japan, India, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape: In-depth analysis of leading companies in the global insomnia pharmacological treatment market.

Available Customizations: TechSci Research offers customized reports based on specific company needs. Customization options include:

• Company Information: Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Insomnia Pharmacological Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug (OTC Drugs, OTC Sleep Aids, OTC Sleep Supplements, Prescription Drugs)
  • 5.2.2. By Treatment (Over-the-Counter Sleep Aids, Prescription Sleep Aids)
  • 5.2.3. By Distribution Channel (Drug Stores, E-Commerce, Hospital Pharmacies, Retail Pharmacies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Insomnia Pharmacological Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug
  • 6.2.2. By Treatment
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Insomnia Pharmacological Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Insomnia Pharmacological Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Insomnia Pharmacological Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Distribution Channel

7. Europe Insomnia Pharmacological Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug
  • 7.2.2. By Treatment
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Insomnia Pharmacological Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Insomnia Pharmacological Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Insomnia Pharmacological Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Insomnia Pharmacological Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Insomnia Pharmacological Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Insomnia Pharmacological Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Insomnia Pharmacological Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Insomnia Pharmacological Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Insomnia Pharmacological Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Insomnia Pharmacological Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Insomnia Pharmacological Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Distribution Channel

9. South America Insomnia Pharmacological Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug
  • 9.2.2. By Treatment
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Insomnia Pharmacological Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Insomnia Pharmacological Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Insomnia Pharmacological Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Insomnia Pharmacological Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug
  • 10.2.2. By Treatment
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Insomnia Pharmacological Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Insomnia Pharmacological Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Insomnia Pharmacological Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Merck & Co Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Ebb Therapeutics Inc/US
• 14.3. Pfizer Inc
• 14.4. Sanofi SA
• 14.5. Takeda Pharmaceutical Co Ltd
• 14.6. Paratek Pharmaceuticals Inc
• 14.7. Electromedical Products International Inc
• 14.8. Meda Pharmaceuticals Inc
• 14.9. Purdue Pharma LP
• 14.10. Pernix Therapeutics Holdings Inc

15. Strategic Recommendations

16. About Us & Disclaimer